CASI Pharmaceuticals, Inc. · OTC:CASIF

CASI Pharmaceuticals — Investor Presentation (May 2014)

7 slides from CASI Pharmaceuticals's investor presentation, May 2014

  1. Slide 1: CASI Pharmaceuticals, Inc.

    CASI Pharmaceuticals, Inc. Your Strategic Drug Development Partner in China NASDAQ: CASI WWW.CASIPHARMACEUTIALS.COM

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance, strategies, expectations and goals. Forward-looking statement

  3. Slide 3: Who We Are

    Who We Are • CASI Pharmaceuticals, Inc. is a US-headquartered, NASDAQ-listed biopharmaceutical company with a dedicated regional focus and strong presence in China • Focused on the acquisition, development, and commercialization of oncology assets for China and other global markets • Core competency

  4. Slide 4: What We Can Do For You

    What We Can Do For You • Launch your product in China up to three years sooner than a more traditional development approach • Have your global Phase 3 programs completed faster • Accelerate your Phase 1 and 2 clinical candidates and reach “proof-of- concept” inflection points or expand into addition

  5. Slide 5: Why China?

    Why China? China’s pharmaceutical spending is expected to grow 14-17% per annum over the next 5 years, reaching $170 billion and becoming the 2nd largest market in the world by 2017. Now is the time to gain a foothold in the Chinese market. Slide 5

  6. Slide 6: Why China Oncology?

    Why China Oncology? China’s oncology market is growing at a rapid rate due to an increase in cancer incidence. It will likely become the world’s largest market in the next 5-10 years. Slide 6

  7. Slide 7: A Seasoned, Bi-Cultural Board and Senior Management Team

    A Seasoned, Bi-Cultural Board and Senior Management Team BOARD OF DIRECTORS OFFICERS Dr. Wei-Wu He, Chairman Dr. Ken K. Ren, CEO CEO and Chairman of OriGene Technologies, Inc.; healthcare venture partner of Formerly an entrepreneur and seasoned executive with healthcare companies, IDG-Accel, a major

CASI Pharmaceuticals — Investor Presentation (May 2014) on 6ix